Consumer Group Urges FDA to Reject Arena Pharmaceuticals, Inc. Diet Drug
Published: Jun 28, 2012
Watchdog group Public Citizen urged U.S. regulators on Tuesday not to approve Arena Pharmaceuticals Inc's experimental diet pill lorcaserin, citing concerns it could increase patients' risk of heart valve damage. The U.S. Food and Drug Administration is expected to rule on whether to approve the drug by Wednesday. Public Citizen, a nonprofit consumer advocacy group, said physicians at last month's FDA advisory panel meeting on lorcaserin raised serious concerns about evidence of increased valve disease risks in patients who used the drug in clinical trials. The panel of independent experts voted 18 to 4 to recommend approval of the pill despite the concerns.